Telcare Pioneers Development of the First Cellular-Enabled Glucometer, Secures Patent Allowance for Critical Technology That Supports Improved Diabetes Management
Company Continues Technical LeadershipWith Patent Allowance for the Technology Critical in Radio-Enabled Glucometers
Telcare, the provider of the world's first cellular-enabled blood glucometer, diabetes mobile application, and comprehensive HIPAA compliant cloud platform, today announced it has been notified by the United States Patent and Trademark Office that multiple claims have been allowed under its pending US patent application covering the company's cellular-enabled blood glucometer.
The allowed patent claims address two areas, the first of which is the engineering steps that must be taken to prevent the radio from interfering with the accuracy of the blood glucose measurement. The second area addressed is preventing the glucometer components from interfering with the cellular radio, which is critical to the meter's data transmission and two-way messaging capabilities.
"Diabetes is a growing problem within the US population. Patients, providers, and payers are spending an increasing amount of resources improving the lives of people living with diabetes while also lowering costs. Healthcare apps are flooding the market and there is a lot of confusion about which solutions can demonstrate positive patient outcomes," said Maureen O'Connor, President of Mosaic Health Solutions. "In health care, trust is earned through improved outcomes and Telcare has a strong track record in delivering positive results and demonstrating leadership in the space."
A first-of-its-kind among diabetes monitoring solutions, the technology addressed in the patent allowance is designed to eliminate the electrical and thermal radio interference that is a potential byproduct of combining meter and electronic transmission functionality in a single device. By safeguarding the integrity of blood glucose readings, Telcare's innovative technology is able to deliver accurate, sensitive medical data to patients and providers in near-real time. Paired with robust analytic capabilities, this new technology further strengthens Telcare's ability to partner with consumers and provider to provide powerful and timely insights for engaging patients and promoting improved care.
"Our glucometer is at the center of a much broader solution set focused on improving the lives of people living with diabetes," said Andrew Flanagan, chief executive officer at Telcare. "We have a long history of trusted technology credentials and securing the allowance for this patent is just one example of what is ahead for Telcare."
"Telcare has been a leader in the diabetes management market for several years and its blood glucose monitoring solution is truly state-of-the-art technology," said Casper de Clercq, partner at Norwest Venture Partners, the venture capital firm that led Telcare's recent $32.5 million round of fundraising. "There is a tremendous opportunity within Digital Health for cost effective remote patient monitoring by making essential health parameters such as blood glucose available through a HIPAA compliant service. Securing this patent allowance validates Telcare's innovative engineering approach and further bolsters Telcare's leadership position."
The technology granted in the patent allowance is already available in Telcare's blood glucometer.
About Telcare Telcare is a leading digital-health company whose pioneering work includes development of the first FDA-cleared cellular blood glucometer. Headquartered in Bethesda, Maryland, Telcare is a privately-held company funded by Norwest Venture Partners, The Qualcomm Life Fund, Sequoia Capital, Mosaic Health Solutions and other founding investors. For more information, visit www.telcare.com.